Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men

Science Translational Medicine

Volumn 4, Issue 151, 2012, Pages

  Anderson, Peter L ^a   Glidden, David V ^b   Liu, Albert ^c   Buchbinder, Susan ^b,c   Lama, Javier R ^d,e   Guanira, Juan Vicente ^e   McMahan, Vanessa ^f   Bushman, Lane R ^a   Casapía, Martín ^g   Montoya Herrera, Orlando ^h   Veloso, Valdilea G ⁱ   Mayer, Kenneth H ^j,k   Chariyalertsak, Suwat ^l   Schechter, Mauro ^m   Bekker, Linda Gail ⁿ   Kallás, Esper Georges ^o,p   Grant, Robert M ^b,f  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^d Investigaciones Medicas en Salud   (Peru)

^e ASOCIACIÓN CIVIL IMPACTA SALUD Y EDUCACIÓN   (Peru)

^f GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^g ASOCIACIÓN CIVIL SELVA AMAZÓNICA   (Peru)

^h Fundación Ecuatoriana Equidad   (Ecuador)

ⁱ Funda??o Oswaldo Cruz   (Brazil)

^j BROWN UNIVERSITY   (United States)

^k FENWAY INSTITUTE   (United States)

^l CHIANG MAI UNIVERSITY   (Thailand)

^m FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

ⁿ UNIVERSITY OF CAPE TOWN   (South Africa)

^o UNIVERSITY OF SÃO PAULO   (Brazil)

^p Instituto de Investigação em Imunologia   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INFECTION RISK; MALE; MALE HOMOSEXUAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK REDUCTION;

ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; ORGANOPHOSPHONATES;

EID: 84866283847     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004006     Document Type: Article

References (27)

1. R. M. Grant, J. R. Lama, P. L. Anderson, V. McMahan, A. Y. Liu, L. Vargas, P. Goicochea, M. Casapía, J. V. Guanira-Carranza, M. E. Ramirez-Cardich, O. Montoya-Herrera, T. Fernández, V. G. Veloso, S. P. Buchbinder, S. Chariyalertsak, M. Schechter, L. G. Bekker, K. H. Mayer, E. G. Kallás, K. R. Amico, K. Mulligan, L. R. Bushman, R. J. Hance, C. Ganoza, P. Defechereux, B. Postle, F. Wang, J. J. McConnell, J. H. Zheng, J. Lee, J. F. Rooney, H. S. Jaffe, A. I. Martinez, D. N. Burns, D. V. Glidden; iPrEx Study Team, Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587- 2599 (2010).
2. UNAIDS, 2010.
3. S. Baral, F. Sifakis, F. Cleghorn, C. Beyrer, Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000-2006: A systematic review. PLoS Med. 4, e339 (2007).
4. D. Donnell et al., paper presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5 to 8 March 2012.
5. S. S. Karim, A. D. Kashuba, L. Werner, Q. A. Karim, Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: Implications for HIV prevention in women. Lancet 378, 279-281 (2011).
6. M. C. Thigpen et al., paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, 2011.
7. L. Van Damme et al., paper presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5 to 8 March 2012.
8. R. J. A. Little, Missing-data adjustments in large surveys. J. Bus. Econ. Stat. 6, 287 - 296 (1988).
9. J. L. Schafer, Multiple imputation: A primer. Stat. Methods Med. Res. 8, 3-15 (1999).
10. A. D. Kashuba, K. B. Patterson, J. B. Dumond, M. S. Cohen, Pre-exposure prophylaxis for HIV prevention: How to predict success. Lancet 379, 2409- 2411 (2012).
11. P. L. Anderson et al., paper presented at the 19th Conference on Retroviruses and Opportunistic Infection, Seattle, WA, 2012.
12. K. B. Patterson, H. A. Prince, E. Kraft, A. J. Jenkins, N. J. Shaheen, J. F. Rooney, M. S. Cohen, A. D. Kashuba, Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci. Transl. Med. 3, 112re4 (2011).
13. P. Anton et al., paper presented at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011.
14. M. J. Keller, R. P. Madan, N. M. Torres, M. J. Fazzari, S. Cho, S. Kalyoussef, G. Shust, P. M. Mesquita, N. Louissaint, J. Chen, H. W. Cohen, E. C. Diament, A. C. Lee, L. Soto-Torres, C.W. Hendrix, B. C. Herold, A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 6, e16475 (2011).
15. L. R. Bushman, J. J. Kiser, J. E. Rower, B. Klein, J. H. Zheng, M. L. Ray, P. L. Anderson, Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J. Pharm. Biomed. Anal. 56, 390-401 (2011).
16. J. Castillo-Mancilla et al., paper presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5 to 8 March 2012.
17. A. Liu et al., paper presented at the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010.
18. K. Borroto-Esoda, J. E. Vela, F. Myrick, A. S. Ray, M. D. Miller, In vitro evaluation of the anti- HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir. Ther. 11, 377-384 (2006).
19. P. L. Anderson et al., paper presented at the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 27 February to 2 March 2011.
20. J. G. García-Lerma, M. E. Cong, J. Mitchell, A. S. Youngpairoj, Q. Zheng, S. Masciotra, A. Martin, Z. Kuklenyik, A. Holder, J. Lipscomb, C. P. Pau, J. R. Barr, D. L. Hanson, R. Otten, L. Paxton, T. M. Folks, W. Heneine, Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci. Transl. Med. 2, 14ra4 (2010).
21. R. Grant et al., paper presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, 2011.
22. T. Delahunty, L. Bushman, B. Robbins, C. V. Fletcher, The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 1907 - 1914 (2009).
23. G. Baheti, J. J. Kiser, P. L. Havens, C. V. Fletcher, Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob. Agents Chemother. 55, 5294 -5299 (2011).
24. J. J. Kiser, C. V. Fletcher, P. M. Flynn, C. K. Cunningham, C. M. Wilson, B. G. Kapogiannis, H. Major-Wilson, R. M. Viani, N. X. Liu, L. R. Muenz, D. R. Harris, P. L. Havens; Adolescent Trials Network for HIV/AIDS Interventions, Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 52, 631-637 (2008).
25. StataCorp, Stata 12.1 (StataCorp LP, College Station, TX, 2011).
26. D. V. Glidden, E. Vittinghoff, Modelling clustered survival data from multicentre clinical trials. Stat. Med. 23, 369-388 (2004).
27. R. L. Prentice, N. E. Breslow, Retrospective studies and failure time models. Biometrika 65, 153-158 (1978).